|
|
|
| Identification of a small peptide targeting epithelial adhesion molecule EpCAM |
| ZHU Yichao1 MA Xiaowen2,3 HE Lei2 ZHOU Jiming2,4 PANG Zhijun2 ZHANG Xinlei2 MAO Zhuang1 LI Meng2 |
1.The Brigade of Undergraduates, the Fourth Military Medical University, Shaanxi Province, Xi′an 710032, China;
2.School of Pharmacy, the Fourth Military Medical University, Shaanxi Province, Xi′an 710032, China;
3.Department of Pharmacology, General Hospital of Ji′nan Military Region, Shandong Province, Ji′nan 250000, China;
4.Department of Cardiology, the 153rd Central Hospital of People′s Liberation Army, He′nan Province, Zhengzhou 450000, China |
|
|
|
Abstract Objective To find the molecular target of an esophagus adenocarcinoma specific binding peptide (SNF*). Methods Pull Down and Mass Spectrum were used to identify the potential target; molecular docking, Western blot, laser scanning confocal microscopy, flow cytomertry, RNA interference and gene transfection were used to verify the target of SNF*. Results Epithelial adhesion molecule (EpCAM) was the potential target of SNF*. SNF* specifically bound with EpCAM which overexpressed in colon cancer cells and tissues. Conclusion Except esophagus adenocarcinoma, SNF* can be used in the early diagnosis and targeted therapy in colorectal cancer with high EpCAM expression.
|
|
|
|
|
|
[1] Dey N，Williams C，Leyland-Jones B. Mutation matters in precision medicine：A future to believe in [J]. Cancer Treat Rev，2017，55：136-149.
[2] Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development [J]. Drug Discov Today，2017，22（8）：1148-1164.
[3] Ahmadyousefi Y，Malih S. Nucleic acid aptamers in diagnosis of colorectal cancer [J]. Biochimie，2018，9：2234-2237.
[4] Ryan JM，Wasser JS，Adler AJ，et al. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit [J]. Expert Opin Biol Ther，2016，16（5）：655-674.
[5] Gorovits B，Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake [J]. Cancer Immunol Immunother，2013，62（2）：217-223.
[6] Le Joncour V，Laakkonen P. Seek & Destroy，use of targeting peptides for cancer detection and drug delivery [J]. Bioorg Med Chem，2018，26（10）：2797-2806.
[7] Li M，Anastassiades CP，Joshi B，et al. Affinity peptide for targeted detection of dysplasia in Barrett′s esophagus [J]. Gastroenterology，2010，139（5）：1472-1480.
[8] Litvinov SV，Balzar M，Winter MJ. Epithelial cell adhesion molecule（Ep-CAM）modulates cell-cell interactions [J]. J Cell Biol，1997，139（5）：1337-1348.
[9] Münz M，Kieu C，Mack B. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation [J]. Oncogene，2004，23（34）：5748-5758.
[10] Maetzel D，Denzel S，Mack B. Nuclear signalling by tumour-associated antigen EpCAM [J]. Nat Cell Biol，2009， 11（2）：162-171.
[11] Atlas of Genetics and Cytogenetics in Oncology and Haematology [EB/OL].（2018-09-26）. http：//AtlasGeneticsOncology.org/Genes/TACSTD1ID42459ch2p21.html.
[12] Tayama S，Motohara T，Narantuya D. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients [J]. Oncotarget，2017，8（27）：44312-44325.
[13] van der Gun BT，Melchers LJ，Ruiters MH. EpCAM in carcinogenesis：the good，the bad or the ugly [J]. Carcinogenesis，2010，31（11）：1913-1921.
[14] Bokemeyer C，Stein A. A phase Ⅱ study of catumaxomab administered intra- and postoperatively in primarily resectable gastric cancer [J]. Gastric Cancer，2015，18（4）：833-842.
[15] Fossati M，Buzzonetti A，Monego G. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the antibody catumaxomab [J]. Gynecol Oncol，2015，138（2）：343-351.
[16] Joshi BP，Wang TD. Gastrointestinal imaging in 2015：Emerging trends in endoscopic imaging [J]. Nat Rev Gastroenterol Hepatol，2016，13（2）：72-73.
[17] Craik DJ，Fairlie DP，Liras S，et al. The future of peptide-based drugs [J]. Chem Biol Drug Des，2013，81（1）：136-147.
[18] Thundimadathil J. Cancer treatment using peptides：current therapies and future prospects [J]. J Amino Acids，2012，2012：967347.
[19] Akerman ME，Chan WC，Laakkonen P，et al. Nanocrystal targeting in vivo [J]. Proc Natl Acad Sci U S A，2002，99（20）：12617-12621.
[20] Laakkonen P，Akerman ME，Biliran H，et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells [J]. Proc Natl Acad Sci U S A，2004， 101（25）：9381-9386. |
|
|
|
